Saluda Medical raises $75M for spinal cord stimulation

Spinal Tech

Saluda Medical acquired $75 million in equity financing from Boston Scientific and Redmile Group to fund the finishing stages of its Evoke evoked action compound potential-controlled, Closed-Loop Spinal Cord Stimulation System.

It is Saluda's first device, designed for the treatment of chronic intractable pain of the trunk and limbs.

Existing shareholder Medtronic agreed a four-year loan deal with Saluda for the development of the device on June 27.

"This equity financing in combination with our recent debt transaction strategically positions us to fund the final developmental stages of the Evoke SCS System through global commercialization," said John Parker, CEO of Saluda Medical. "We believe [Evoke] has immense potential for radically improving the way pain is treated."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers